Summary
• NeuroSense Therapeutics Ltd. (NRSN) rose 6.4% in pre-market trading to $1.16 following FDA clearance for a Phase 3 trial for its ALS treatment.
• Analyst Jason Kolbert maintains a “Buy” rating with a price target of $14, reflecting confidence in the company’s potential.
• The stock has experienced mixed trading dynamics, with a year-to-date decline of about 22.5% and average trading volume above its three-month average.
NeuroSense Therapeutics Ltd. (NRSN) is experiencing a robust 6.4% increase in pre-market trading, currently priced at $1.16, up from the last closing mark of $1.09. This positive movement follows the recent announcement regarding FDA clearance for a pivotal Phase 3 trial related to its treatment for ALS.
FDA Clearance Sparks Investor Interest
On November 24, 2025, NeuroSense announced that it received FDA clearance to initiate a pivotal Phase 3 trial for its PrimeC treatment targeting ALS. This development is likely to enhance investor sentiment and underscores the company’s commitment to advancing its clinical programs. The pivotal trial marks a significant step forward in the company’s research initiatives, potentially positioning it for future growth in the neurology therapeutics market.
Analysts Maintain Optimistic Outlook
Following the recent developments, analyst Jason Kolbert of D. Boral Capital maintained a “Buy” rating for NRSN, reaffirming a price target of $14. The consistent buy rating indicates a strong belief in the company’s potential as it progresses with its trials.
Market and Technical Picture
NeuroSense has encountered a mixed trading performance recently, reflected in its average volume of approximately 720,923 shares over the last 10 days, which is higher than its three-month average of 604,129 shares. The stock currently has a Relative Strength Index (RSI) of 48.33, indicating it is slightly positioned within neutral territory. Its performance metrics reflect a challenging year-to-date decline of approximately 22.5%, as well as a concerning quarterly performance dipped by about 22.5%.
Closing Thoughts
With the latest FDA clearance now reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session. This pivotal moment in NeuroSense’s trajectory may signal a shift in attention from the market toward the company’s clinical advancements and potential revenue generation avenues.